MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0510
Full Text
Open PDFAbstract
Available in full text
Date
November 13, 2018
Authors
Publisher
American Association for Cancer Research (AACR)